Lymphoproliferative disorders in rheumatoid arthritis: Clinicopathological analysis of 76 cases in relation to methotrexate medication

Journal of Rheumatology

Volumn 34, Issue 2, 2007, Pages 322-331

  Hoshida, Yoshihiko ^a   Xu, Jing Xian ^a   Fujita, Shigeki ^a   Nakamichi, Itsuko ^a   Ikeda, Jun Ichiro ^a   Tomita, Yasuhiko ^a   Nakatsuka, Shin Ichi ^a   Tamaru, Jun Ichi ^b   Iizuka, Atsushi ^b   Takeuchi, Tsutomu ^b   Aozasa, Katsuyuki ^a  

^a OSAKA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b SAITAMA MEDICAL UNIVERSITY   (Japan)

Author keywords

Epstein Barr virus; Hyperimmune state; Immunosuppressive state; Lymphoproliferative disorders; Methotrexate; Rheumatoid arthritis

Indexed keywords

AUROTHIOMALATE; BUCILLAMINE; CYCLOPHOSPHAMIDE; METHOTREXATE; PENICILLAMINE; PREDNISOLONE; SALAZOSULFAPYRIDINE;

ADULT; AGED; ARTICLE; AUTOPSY; B CELL LYMPHOMA; CANCER REGRESSION; DIAGNOSTIC VALUE; EPSTEIN BARR VIRUS; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOSTIMULATION; LARGE CELL LYMPHOMA; LYMPHOPROLIFERATIVE DISEASE; MAJOR CLINICAL STUDY; MALE; ONSET AGE; PRIORITY JOURNAL; PROGNOSIS; RHEUMATOID ARTHRITIS; SEX DIFFERENCE; SURVIVAL RATE;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; EPSTEIN-BARR VIRUS INFECTIONS; FEMALE; HERPESVIRUS 4, HUMAN; HUMANS; IMMUNOCOMPROMISED HOST; IMMUNOENZYME TECHNIQUES; IMMUNOPHENOTYPING; IMMUNOSUPPRESSIVE AGENTS; IN SITU HYBRIDIZATION; LYMPHOMA, LARGE-CELL, DIFFUSE; LYMPHOPROLIFERATIVE DISORDERS; MALE; METHOTREXATE; MIDDLE AGED; NEOPLASM STAGING; ORGAN TRANSPLANTATION; RNA, VIRAL; SURVIVAL RATE;

EID: 33847003656     PISSN: 0315162X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (45)

1. Harris NL, Swerdlow SH. Methotrexate-associated lymphoproliferative disorders. In: Jaffe ES, Harris NL, Stein H, Vardiman JW, editors. Pathology and genetics, tumours of haematopoietic and lymphoid tissues. World Health Organization classification of tumours. Lyon: IARC Press: 2001:270-1.
2. Symmons DP. Neoplasms of the immune system in rheumatic arthritis. Am J Med 1985;78:22-8.
3. Isomaki HA, Hakulinen T, Joutsenlahti U. Excess risk of lymphomas, leukemia and myeloma in patients with rheumatoid arthritis. J Chron Dis 1978;31:691-6.
4. Ellman MH, Hurwitz H, Thomas C, Kozloff M. Lymphoma developing in a patient with rheumatoid arthritis taking low dose weekly methotrexate. J Rheumatol 1991;18:1741-3.
5. Salloum E, Doria R, Schubert W, et al. Spontaneous regression of lymphoproliferative disorders in patients treated with methotrexate for rheumatoid arthritis and other rheumatic diseases. J Clin Oncol 1996;14:1943-9.
6. Mariette X, Cazals-Hatem D, Warszawki J, Liote F, Balandraud N, Sibilia J. Investigators of the Club Rhumatismes et Inflammation. Lymphomas in rheumatoid arthritis patients treated with methotrexate: a 3-year prospective study in France. Blood 2002;99:3909-15.
7. Menke DM, Griesser H, Moder KG, et al. Lymphomas in patients with connective tissue disease. Comparison of p53 protein expression and latent EBV infection in patients immunosuppressed and not immunosuppressed with methotrexate. Am J Clin Pathol 2000;113:212-8.
8. Kamel OW, van de Rijn M, Weiss LM, et al. Brief report: Reversible lymphomas associated with Epstein-Barr virus occurring during therapy for rheumatoid arthritis and dermatomyositis. N Engl J Med 1993;328:1317-21.
9. Kamel OW, van de Rijn M, LeBrun DP, Weiss LM, Warnke RA, Dorfman RF. Lymphoid neoplasms in patients with rheumatoid arthritis and dermatomyositis: frequency of Epstein-Barr virus and other features associated with immunosuppression. Hum Pathol 1994;25:638-43.
10. Kingsmore SF, Hall BD, Allen NB, Rice JR, Caldwell DS. Association of methotrexate, rheumatoid arthritis and lymphoma: Report of 2 cases and literature review. J Rheumatol 1992;19:1462-5.
11. Moder KG, Tefferi A, Cohen MD, Menke DM, Luthra HS. Hematologic malignancies and the use of methotrexate in rheumatoid arthritis: a retrospective review. Am J Med 1995;99:276-82.
12. Thomas E, Brewster DH, Black RJ, Macfarlane GJ. Risk of malignancy among patients with rheumatic conditions. Int J Cancer 2000;88:497-50.
13. Mellemkjaer L, Linet MS, Gridley G, Frisch M, Moller H, Olsen JH. Rheumatoid arthritis and cancer risk. Eur J Cancer 1996;32A:1753-7.
14. Gridley G, McLaughlin JK, Ekbom A, et al. Incidence of cancer among patients with rheumatoid arthritis. J Natl Cancer Inst 1993;85:307-11.
15. Starkebaum G. Rheumatoid arthritis, methotrexate, and lymphoma: risk substitution, or eat and mouse with Epstein-Barr virus? J Rheumatol 2001;28:2573-5.
16. Chan ESL, Cronstein BN. Molecular action of methotrexate in inflammatory diseases. Arthritis Res 2002;4:266-73.
17. Arnett FC, Edworthy SM, Bloch DA, et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988;31:315-24.
18. Ropes MW, Bennett GA, Cobb S, Jacox R, Jessar RA. 1958 Revision of diagnostic criteria for rheumatoid arthritis. Bull Rheum Dis 1958;9:175-6.
19. Hoshida Y, Tomita Y, Dong Z, et al. Lymphoproliferative disorders in autoimmune diseases in Japan: Analysis of clinicopathological features and Epstein-Barr virus infection. Int J Cancer 2004;108:443-9.
20. Kwok S, Ehrlich G, Poiesz B, Kalish R, Sninsky JJ. Enzymatic amplification of HTLV-1 viral sequences from peripheral blood mononuclear cells and infected tissues. Blood 1988;72:1117-23.
21. Weiss LM, Chen YY, Liu XF, Shibata D. Epstein-Barr virus and Hodgkin's disease: a correlative in situ hybridization and polymerase chain reaction study. Am J Pathol 1991;139:1259-65.
22. Harrel FE, Lee KL, Matchar DB, Reichert TA. Regression models for prognostic prediction: advantages, problems, and suggested solutions. Cancer Treat Rep 1985;69:1071-7.
23. Kaplan EL, Meier P. Non-parametric estimation from incomplete observations. J Am Statist Assoc 1958;53:457-81.
24. Peto RE, Pike MC, Armitage P, et al. Design and analysis of randomized clinical trials requiring prolonged observation of each patient. Br J Cancer 1977;35:1-39.
25. Cox DR. Regression models and life-tables. J R Stat Soc 1972;34:187-220.
26. Hoshida Y, Yamamoto S, Wada N, Xu J-X, Sasaki T, Aozasa K. Infliximab-associated lymphoproliferative disorders (LPD). Int J Hematol 2005;81:356-7.
27. Cheson BD, Horning SJ, Coiffier B, et al. Report of an international workshop to standardize response criteria for non-Hodgkin's lymphoma. J Clin Oncol 1999;17:1244-53.
28. Hoshida Y, Li T, Dong Z, et al. Lymphoproliferative disorders in renal transplants in Japan. Int J Cancer 2001;91:869-75.
29. Levine AM, Seneviratne L, Espina BM, et al. Evolving characteristics of AIDS-related lymphoma. Blood 2000;96:4086-90.
30. Aozasa K, Tsujimoto M, Sakurai M, et al. Non-Hodgkin's lymphomas in Osaka, Japan. Eur J Cancer Clin Oncol 1985;21:487-92.
31. Lipsky PE. Rheumatoid arthritis. In: Braunwald E, Hauser SL, Fauci AS, editors. Harrison's principles of internal medicine. 15th ed. New York: McGraw-Hill Inc.; 2001:1928-37.
32. Baecklund E, Iliadou A, Askling J, et al. Association of chronic inflammation, not its treatment, with increased lymphoma risk in rheumatoid arthritis. Arthritis Rheum 2006;54:692-701.
33. Mikuls TR, Endo JO, Puumalu SE, et al. Prospective study of survival outcomes in non-Hodgkin's lymphoma patients with rheumatoid arthritis. J Clin Oncol 2006;24:1597-602.
34. Kojima M, Itoh H, Shimizu K, et al. Malignant lymphoma in patients with systemic rheumatic disease (rheumatoid arthritis, systemic lupus erythematosus, systemic sclerosis, and dermatomyositis): a clinicopathologic study of 24 Japanese cases. Int J Surg Pathol 2006;14:43-8.
35. Raphael M, Borisch B, Jaffe ES. Lymphoma associated with infection by the human immune deficiency virus (HIV). In: Jaffe ES, Harris NL, Stein H, Vardiman JW, editors. Pathology and genetics, tumours of haematopoietic and lymphoid tissues, World Health Organization Classification of tumours. Lyon: IARC Press;2001:260-3.
36. Baecklund E, Sundstrom C, Ekhom A, et al. Lymphoma subtypes in patients with rheumatoid arthritis: increased proportion of diffuse large B cell lymphoma. Arthritis Rheum 2003;48:1543-50.
37. Chadburn A, Chen JM, Hsu DT, et al. The morphologic and molecular genetic categories of post-transplantation lymphoproliferative disorders are clinically relevant. Cancer 1998;82:1978-87.
38. Leblond V, Sutton L, Dorent R, et al. Lymphoproliferative disorders after organ transplantation: a report of 24 cases observed in a single center. J Clin Oncol 1995;13:961-8.
39. Hoshida Y, Aozasa K. Malignancies in organ transplant recipients. Pathol Int 2004;54:649-58.
40. Nalesnik MA, Jaffe R, Starzl TE, et al. The pathology of post-transplant lymphoproliferative disorders occurring in the setting of cyclosporine A prednisone immunosuppression. Am J Pathol 1988;133:173-92.
41. Weyand CM, Goronzy JJ, Kurtin PJ. Lymphoma in rheumatoid arthritis: an immune system set up for failure. Arthritis Rheum 2006;54:685-9.
42. Kamel OW, Holly EA, van de Rijn M, Lele C, Sah A. A population based, case control study of non-Hodgkin's lymphoma in patients with rheumatoid arthritis. J Rheumatol 1999;26:1676-80.
43. Kamel OW, Weiss LM, van de Rijn M, Colby TV, Kingma DW, Jaffe ES. Hodgkin's disease and lymphoproliferations resembling Hodgkin's disease in patients receiving long-term low-dose methotrexate therapy. Am J Surg Pathol 1996;20:1279-87.
44. Feng WH, Cohen JT, Fischer S, et al. Reactivation of latent Epstein-Barr virus by methotrexate; a potential contributor to methotrexate-associated lymphomas. J Natl Cancer Inst 2004;96:1691-702.
45. The T- and B-Cell Malignancy Study Group. Statistical analysis of clinico-pathological, virological, and epidemiological data on lymphoid malignancies with special reference to adult T-cell leukemia/lymphoma: a report of the second nationwide study of Japan. Jpn J Clin Oncol 1985;15:517-35.